James M. Frates, Chief Financial Officer at Amylyx Pharmaceuticals, Inc. (AMLX), bought 80,000 shares at $2.53 ($202K) on 2024-09-12, disclosed to the SEC on 2024-09-16.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.53 | 40,000 | $101K | 50.0% |
| 2 | $2.53 | 40,000 | $101K | 50.0% |
| Total | $2.53 avg | 80,000 | $202K | 100% |
| Filing → |
| AMLX | SELL | 2026-02-04 | $52K | — | Filing → |
| AMLX | SELL | 2026-01-08 | $37K | — | Filing → |
| AMLX | SELL | 2025-10-02 | $309K | — | Filing → |